We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Enrolment of new patients in the TELLOMAK trial, which has been evaluating the efficacy and safety of lacutamab in patients with advanced T-cell lymphomas, has been suspended.
France’s Innate Pharma has gained rights to AstraZeneca’s recently approved leukaemia drug Lumoxiti, in a deal that expands a collaboration that began more than three years ago.
French biotechnology company Innate Pharma has signed an agreement to acquire a clinical-stage anti-C5a receptor (C5aR) antibody (IPH5401) from Danish pharmaceutical firm Novo Nordisk for €40m.